NDA 021994 · Sandoz
Travatan Z
Travoprost · Ophthalmic · Prostaglandin Analog
Last checked: Nov 20, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Sep 21, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
137
36 Phase 3, 4 recruiting
FAERS reports
8,671
3,182 serious, 333 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 31, 2025.
TRAVATAN Z ® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. TRAVATAN Z is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension (1)
Mechanism: Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 31, 2010 Supplement 1 · Efficacy LabelLetter
- Sep 21, 2006 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
1 products under this application
- TRAVATAN Z · TRAVOPROST 0.004% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT2
Clinical trials
Interventional ClinicalTrials.gov studies with "Travoprost" as an intervention, any sponsor and status, largest first.
- Travoprost 3-Month Safety and Efficacy StudyPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01453855 · 1,099 participants · Start Nov 2011 · Primary completion Aug 2012
Drug: Travoprost ophthalmic solution, 0.003%; Travoprost ophthalmic solution, 0.004% · For: Open-Angle Glaucoma; Ocular Hypertension
Alcon ResearchIndustry
NCT00444665 · 750 participants (planned) · Start May 2007 · Primary completion Aug 2007
Drug: Travatan-Z · For: Glaucoma
Sites: Fridley, Minnesota
- Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00690794 · 726 participants · Start Jul 2008 · Primary completion May 2009
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®) · For: Open-angle Glaucoma; Ocular Hypertension
- Phase III Clinical Trial of TRAVATAN Z in Ocular Surface HealthPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00761319 · 705 participants · Start Oct 2008 · Primary completion Sep 2009
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®) · For: Open-angle Glaucoma; Ocular Hypertension
- Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension PatientsPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00288951 · 690 participants · Start Oct 2004 · Primary completion Jun 2005
Drug: Travoprost 0.004% with and without BAK · For: Open-angle Glaucoma; Ocular Hypertension
- Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%Pivotal-lookingCompleted
Glaukos CorporationIndustry
NCT03519386 · 590 participants · Start Jul 26, 2018 · Primary completion Apr 5, 2022
Drug: Sham surgery + active-comparator eye drops · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Sioux Falls, South Dakota
- Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHTPivotal-lookingCompleted
Ocular Therapeutix, Inc.Industry
NCT02914509 · 565 participants · Start Nov 7, 2016 · Primary completion Mar 30, 2019
Drug: Travoprost · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Artesia, California; Colorado Springs, Colorado; Lakeland, Florida · 10 sites in all
- Clinical Study Comparing Two Models of a Travoprost Intraocular ImplantPivotal-lookingCompleted
Glaukos CorporationIndustry
NCT03868124 · 560 participants · Start Sep 17, 2018 · Primary completion Jun 10, 2022
Drug: Sham surgery + active-comparator eye drops · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Las Vegas, Nevada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure1,951
- drug ineffective545
- ocular hyperaemia503
- eye irritation499
- eye pain352
- intraocular pressure increased299
- hypersensitivity269
- fatigue268
- glaucoma260
- headache237
- dizziness236
- vision blurred236
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 47 |
| 2006 | 32 |
| 2007 | 35 |
| 2008 | 37 |
| 2009 | 55 |
| 2010 | 68 |
| 2011 | 85 |
| 2012 | 114 |
| 2013 | 113 |
| 2014 | 164 |
| 2015 | 361 |
| 2016 | 633 |
| 2017 | 821 |
| 2018 | 792 |
| 2019 | 743 |
| 2020 | 2,608 |
| 2021 | 483 |
| 2022 | 355 |
| 2023 | 291 |
| 2024 | 253 |
| 2025 | 325 |
| 2026 | 240 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Travatan Z (Travoprost)
2024 spending
$10.6M
Beneficiaries
5,919
21,212 claims
Per beneficiary
$1,790
$91.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,141,146 |
| 2021 | $19,268,531 |
| 2022 | $14,924,685 |
| 2023 | $12,901,633 |
| 2024 | $10,595,167 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Sarkisian SR, Ang RE, Lee AM, et al. · Ophthalmology 2024 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of travoprost for the treatment of patients with glaucoma.
Zhang XL, Qin L · Medicine (Baltimore) 2019 · Systematic Review
- Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression.
Schmier JK, Halpern MT, Covert DW, et al. · Curr Med Res Opin 2006 · Clinical Trial, Phase III, Multicenter Study
- Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes.
Hutchison DM, Duffens A, Yale K, et al. · J Eur Acad Dermatol Venereol 2022 · Systematic Review
- Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
Aptel F, Cucherat M, Denis P · J Glaucoma 2008 · Comparative Study, Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.